Current research demonstrates that sildenafil may serve as a potential agent for the treatment of lung cancer by inhibiting CYP3A4 through in vitro enzymatic assays, drug interaction investigations and pharmacokinetic studies (59). The gene discussed is CYP3A4; the disease is lung cancer.